Literature DB >> 21167521

Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma.

Ari Adamy1, Kian Tai Chong, Daher Chade, James Costaras, Grace Russo, Matthew G Kaag, Melanie Bernstein, Robert J Motzer, Paul Russo.   

Abstract

PURPOSE: We analyzed characteristics in patients with recurrent renal cell carcinoma 5 years or later after nephrectomy and determined predictors of survival after recurrence.
MATERIALS AND METHODS: From July 1989 to October 2008 at total of 2,368 nephrectomies were done for clinically localized, unilateral renal cell carcinoma at our institution. Of 256 patients with disease recurrence 44 had recurrence 5 years or more after nephrectomy. We compared clinicopathological characteristics in patients with disease recurrence before vs after 5 years. Survival from time of recurrence was assessed based on Memorial Sloan-Kettering Cancer Center risk score, symptoms at recurrence, metastasectomy, tumor diameter, and recurrence stage and site.
RESULTS: Patients with late recurrence tended to have fewer symptoms at presentation, smaller tumors (median 8.5 vs 7 cm) and less aggressive disease (pT1 in 18% vs 39%). Median overall survival was 6.1 years from time of recurrence. Five-year actuarial survival was 85% in 28 patients at favorable risk and 14% in 10 at intermediate risk (log rank p <0.001). The 5-year estimated overall survival rate was 72% in 31 patients with incidentally detected recurrence and 39% in 11 with symptoms at recurrence (log rank p = 0.01).
CONCLUSIONS: Data suggest that patients with cancer recurrence 5 years after nephrectomy are at favorable risk and have long-term median survival. A favorable Memorial Sloan-Kettering Cancer Center risk score and absent symptoms related to metastasis are associated with longer survival in these patients. Copyright Â
© 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21167521     DOI: 10.1016/j.juro.2010.09.100

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  26 in total

1.  Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma.

Authors:  Wassim Kassouf; Leonardo L Monteiro; Darrel E Drachenberg; Adrian S Fairey; Antonio Finelli; Anil Kapoor; Jean-Baptiste Lattouf; Michael J Leveridge; Nicholas E Power; Frederic Pouliot; Ricardo A Rendon; Robert Sabbagh; Alan I So; Simon Tanguay; Rodney H Breau
Journal:  Can Urol Assoc J       Date:  2018-05-31       Impact factor: 1.862

Review 2.  Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data.

Authors:  Jacqueline M Speed; Quoc-Dien Trinh; Toni K Choueiri; Maxine Sun
Journal:  Curr Urol Rep       Date:  2017-02       Impact factor: 3.092

3.  Time-dependent change in relapse sites of renal cell carcinoma after curative surgery.

Authors:  Go Noguchi; Noboru Nakaigawa; Masataka Taguri; Sohgo Tsutsumi; Yoko Saito; Sachi Fukui; Masato Yasui; Takashi Tokita; Taku Mitome; Tomoyuki Tatenuma; Shinnosuke Kuroda; Koichi Abe; Daiki Ueno; Kazuhiro Namura; Susumu Umemoto; Akitoshi Takizawa; Junichi Ohta; Teiichiro Ueki; Takeshi Watanabe; Kazuki Kobayashi; Keiichi Kondo; Takeshi Kishida; Hitomi Kanno; Kazuo Kitami; Takeharu Yamanaka; Masahiro Yao
Journal:  Clin Exp Metastasis       Date:  2018-03-07       Impact factor: 5.150

Review 4.  Post partial nephrectomy surveillance imaging: an evidence-based approach.

Authors:  Lorenzo Marconi; Michael A Gorin; Mohamad E Allaf
Journal:  Curr Urol Rep       Date:  2015-04       Impact factor: 3.092

5.  ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.

Authors:  Samira A Brooks; A Rose Brannon; Joel S Parker; Jennifer C Fisher; Oishee Sen; Michael W Kattan; A Ari Hakimi; James J Hsieh; Toni K Choueiri; Pheroze Tamboli; Jodi K Maranchie; Peter Hinds; C Ryan Miller; Matthew E Nielsen; W Kimryn Rathmell
Journal:  Eur Urol       Date:  2014-02-25       Impact factor: 20.096

6.  Prognostic indicators of pulmonary metastasis in patients with renal cell carcinoma who have undergone radical nephrectomy.

Authors:  Ja Yoon Ku; Suk Kim; Seung Baek Hong; Jong Geun Lee; Chan Ho Lee; Seock Hwan Choi; Hong Koo Ha
Journal:  Oncol Lett       Date:  2019-01-09       Impact factor: 2.967

Review 7.  Is there a role for adjuvant therapy after surgery in "high risk for recurrence" kidney cancer? An update on current concepts.

Authors:  T Sharma; C Tajzler; A Kapoor
Journal:  Curr Oncol       Date:  2018-10-31       Impact factor: 3.677

8.  Value of metastin receptor immunohistochemistry in predicting metastasis after radical nephrectomy for pT1 clear cell renal cell carcinoma.

Authors:  Sunao Shoji; Mayura Nakano; Tetsuro Tomonaga; Hakushi Kim; Kazuya Hanai; Yukio Usui; Yoshihiro Nagata; Masaki Miyazawa; Haruhiro Sato; Xian Yang Tang; Yoshiyuki Robert Osamura; Toyoaki Uchida; Toshiro Terachi; Koichi Takeya
Journal:  Clin Exp Metastasis       Date:  2013-01-01       Impact factor: 5.150

9.  The blind spots in follow-up after nephrectomy or nephron-sparing surgery for localized renal cell carcinoma.

Authors:  Tim J van Oostenbrugge; Stephanie G C Kroeze; J L H Ruud Bosch; Harm H E van Melick
Journal:  World J Urol       Date:  2014-09-02       Impact factor: 4.226

Review 10.  Follow-up after curative treatment of localised renal cell carcinoma.

Authors:  Saeed Dabestani; Lorenzo Marconi; Teele Kuusk; Axel Bex
Journal:  World J Urol       Date:  2018-05-16       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.